Generalized Anxiety Disorder in the United States: Review & Forecast of the Market & Competitive Landscape, 2014-2024 - ResearchAndMarkets.com

DUBLIN--()--The "US Generalized Anxiety Disorder Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

The latest research provides comprehensive insights into Generalized Anxiety Disorder pipeline products, Generalized Anxiety Disorder epidemiology, Generalized Anxiety Disorder market valuations and forecast, Generalized Anxiety Disorder drugs sales and competitive landscape in the US.

The research is classified into seven sections - Generalized Anxiety Disorder treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.

Research Scope

  • Generalized Anxiety Disorder pipeline: Find out the products in clinical trials for the treatment of Generalized Anxiety Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
  • Generalized Anxiety Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Generalized Anxiety Disorder in the US
  • Generalized Anxiety Disorder drugs: Identify key products marketed and prescribed for Generalized Anxiety Disorder in the US, including trade name, molecule name, and company
  • Generalized Anxiety Disorder drugs sales: Find out the sales revenues of Generalized Anxiety Disorder drugs in the US
  • Generalized Anxiety Disorder market valuations: Find out the market size for Generalized Anxiety Disorder drugs in 2018 in the US. Find out how the market advanced from 2014 and forecast to 2024
  • Generalized Anxiety Disorder drugs market share: Find out the market shares for key Generalized Anxiety Disorder drugs in the US

Benefits of this Research

  • Support monitoring and reporting national Generalized Anxiety Disorder market analysis and sales trends
  • Track competitor drugs sales and market share in the US Generalized Anxiety Disorder market
  • Track competitive developments in Generalized Anxiety Disorder market and present key issues and learnings
  • Synthesize insights for Generalized Anxiety Disorder market and products to drive business performance
  • Answer key business questions about the Generalized Anxiety Disorder market
  • Evaluate commercial market opportunity assessment, positioning, and segmentation for Generalized Anxiety Disorder products
  • Supports decision making in R&D to long term marketing strategies

Key Topics Covered

1) Generalized Anxiety Disorder Treatments

2) Generalized Anxiety Disorder Pipeline

3) US Generalized Anxiety Disorder Epidemiology

4) Marketed Drugs for Generalized Anxiety Disorder in US

5) US Generalized Anxiety Disorder Market Size and Forecast

6) US Generalized Anxiety Disorder Products Sales and Forecast

7) US Generalized Anxiety Disorder Market Competitive Landscape

8) Methodology

9) Contact us

List of Tables

1. Generalized Anxiety Disorder Phase 3 Clinical Trials, 2019

2. Generalized Anxiety Disorder Phase 2 Clinical Trials, 2019

3. Generalized Anxiety Disorder Phase 1 Clinical Trials, 2019

4. Generalized Anxiety Disorder Epidemiology, US, 2014 - 2024

5. Marketed Drugs for Generalized Anxiety Disorder, US, 2018

6. Generalized Anxiety Disorder Market Size and Forecast ($), US, 2014 - 2024

7. Generalized Anxiety Disorder Product Sales ($), US, 2014 - 2024

List of Figures

1. Generalized Anxiety Disorder Epidemiology, US, 2014 - 2024

2. Generalized Anxiety Disorder Market Size and Forecast ($), US, 2014 - 2024

3. Generalized Anxiety Disorder Products Market Share (%), US, 2018

For more information about this report visit https://www.researchandmarkets.com/r/w95ge5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Health, Anxiety Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Health, Anxiety Drugs